Document Detail


Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma.
MedLine Citation:
PMID:  25152703     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Mammalian target of rapamycin (mTOR) is a kinase protein involved in PI3K/AKT signaling with a central role in the processes of cell growth, survival and angiogenesis. Frequent mutations of this pathway make upstream and downstream components novel targets for tailored therapy design. Two mTOR inhibitors - everolimus and temsirolimus - enable an increase in overall survival (OS) or progression-free survival (PFS) time in a treatment of renal cancer. Despite recent advances in renal cancer treatment, resistance to targeted therapy is common. Understanding of molecular mechanisms is the basis of drug resistance which can facilitate prediction of success or failure in combinational or sequential targeted therapy. The article provides current knowledge on the mTOR signaling network and gives insight into the mechanisms of resistance to mTOR inhibitors from the complex perspective of RCC biology. The mechanisms of resistance developed not only by cancer cells, but also by interactions with tumor microenvironment are analyzed to emphasize the role of angiogenesis in ccRCC pathogenesis. As recent studies have shown the role of PI3K/AKT-mTOR pathway in proliferation and differentiation of cancer stem cells, we discuss cancer stem cell hypothesis and its possible contribution to ccRCC resistance. In the context of drug resistance, we also elaborate on a new approach considering ccRCC as a metabolic disease. In conclusion we speculate on future developments in agents targeting the mTOR pathway taking into consideration the singular biology of ccRCC.
Authors:
Anna Kornakiewicz; Wojciech Solarek; Zofia F Bielecka; Fei Lian; Cezary Szczylik; Anna M Czarnecka
Related Documents :
16375643 - Hormonal therapy in epithelial ovarian cancer.
17973323 - Does ifosfamide affect gonadal function?
25341933 - Ncrna combined therapy as future treatment option for cancer.
Publication Detail:
Type:  JOURNAL ARTICLE    
Journal Detail:
Title:  Current signal transduction therapy     Volume:  8     ISSN:  1574-3624     ISO Abbreviation:  Curr Signal Transduct Ther     Publication Date:  2014 Dec 
Date Detail:
Created Date:  2014-8-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101273157     Medline TA:  Curr Signal Transduct Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  210-218     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Development of Receptor Targeted Magnetic Iron Oxide Nanoparticles for Efficient Drug Delivery and T...
Next Document:  Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma...